Literature DB >> 24094522

Adenoid cystic carcinoma in the bronchus behaves more aggressively than its tracheal counterpart.

Yang Zhao1, Heng Zhao, Limin Fan, Jianxin Shi.   

Abstract

BACKGROUND: Primary airway adenoid cystic carcinomas (ACCs) are rare neoplasms and challenging to resect completely. The objective of the current study was to evaluate clinical and pathologic features and indicate prognostic factors based on different tumor locations in the airway.
METHODS: From March 2001 to April 2012, 82 consecutively operated patients were enrolled in this study with pathologically confirmed airway adenoid cystic carcinomas in the Shanghai Chest Hospital. Clinical and pathologic data were retrospectively reviewed. Survival analysis was performed using the Kaplan-Meier and log-rank tests. Multivariate analysis was performed using the Cox regression model.
RESULTS: The ACCs originating from the bronchus were associated with older age (p = 0.021), had fewer positive margins (44.8% vs 84.9%, p < 0.001), and more involved lymph nodes (55.2% vs 14.3%, p = 0.002) than their tracheal counterparts. The overall survival after resection of all ACCs was 90.6% at 5 years and 56.4% at 10 years. Five and 10-year disease-free survival was 66.9% and 11.2%, respectively. Multivariate analysis indentified only dyspnea as a presenting symptom to predict tracheal disease-free survival (hazard ratio = 0.062, 95% confidence interval = 0.005 to 0.785, p = 0.032). Bronchial ACCs had worse disease-free survival than tumors of tracheal origin (p = 0.001).
CONCLUSIONS: Adenoid cystic carcinoma in the bronchus behaves more aggressively than its tracheal counterpart. Only dyspnea as a presenting symptom predicts better disease-free survival after resection of tracheal ACCs.
Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  15

Mesh:

Year:  2013        PMID: 24094522     DOI: 10.1016/j.athoracsur.2013.08.009

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Adenoid cystic carcinoma of the tracheobronchial tree: clinicopathologic and immunohistochemical studies of 21 cases.

Authors:  Zhen Huo; Yunxiao Meng; Huanwen Wu; Jie Shen; Yalan Bi; Yufeng Luo; Jinling Cao; Zhiyong Liang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

2.  A Case of Solid Variant of Adenoid Cystic Carcinoma from Trachea: A Case Report and Review of Literature.

Authors:  Feng Gao; Lijuan Zang; Jin He; Weiqing Xu
Journal:  Onco Targets Ther       Date:  2021-03-18       Impact factor: 4.147

3.  Left secondary carinal resection and reconstruction for low-grade bronchial malignancies.

Authors:  Liang Chen; Alessio Campisi; Zhexin Wang; Andrea Dell'Amore; Angelo Paolo Ciarrocchi; Heng Zhao; Franco Stella; Feng Yao
Journal:  JTCVS Tech       Date:  2021-05-19

4.  Contrast-enhanced CT longitudinal tail sign as a marker of positive resection margins in adenoid cystic carcinoma of the central airway.

Authors:  Shu-Chao Wang; Le-Kang Yin; Yu Zhang; Li-Min Xue; Jian-Ding Ye; Guang-Yu Tao; Hong Yu; Jin-Wei Qiang
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 3.005

5.  Predictors of nodal metastasis and prognostic significance of lymph node ratio and total lymph node count in tracheobronchial adenoid cystic carcinoma.

Authors:  Yang Wo; Shicheng Li; Yuanyong Wang; Tong Lu; Yi Qin; Xiao Sun; Wenjie Jiao
Journal:  Cancer Manag Res       Date:  2018-11-19       Impact factor: 3.989

6.  Surgical treatment of primary tracheobronchial tumors: 16-year experience in a single center.

Authors:  Yujian Liu; Kaifu Zheng; Qiang Lu; Jian Wang; Yunfeng Ni; Xiaolong Yan; Lei Wang; Xiyang Tang; Jing Huang; Xiaofei Li; Jinbo Zhao
Journal:  J Thorac Dis       Date:  2022-02       Impact factor: 2.895

7.  Clinical features and prognosis analysis of 57 patients with primary tracheal tumors.

Authors:  Mao Jiang; Qunjuan Lei; Xin Lv; Lijun Zou; Jingjing Liu; Jie Meng
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.